Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc.

NNASDAQ:KLRS
1.46
USD
-0.11
(-7.30%)
-1.84EPS
68.80MMarket Cap
Mar 23Next Earn
Kalaris Therapeutics, Inc.
NASDAQ:KLRS
(Nasdaq Stock Market)

Recent

price

1.46

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
TTM
USD
- -
- -
- -
- -
- -
Revenue per Share
-11.64
-11.05
-3.7
-2.85
-1.84
Basic EPS, GAAP
-7.35
-10.62
-1.11
-2.53
-1.71
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
-1.62
-2.41
-5.17
3.44
1.99
Book Value per Share
-1.62
-2.41
-5.17
3.44
1.99
Tangible Book Value per Share
1
1
19
15
24
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
-15
-15
-69
-43
-43
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
-2
-1
-22
109
77
Working Capital
3
- -
- -
1
1
LT Debt
-30
-45
-97
79
47
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-97.23
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
24
24
Market Capitalization
133
97
69

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
98
96
85
Cash, Cash Equivalents & STI
97
94
83
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
8
9
9
Payables & Accruals
7
7
7
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-181.57%
Free Cash Flow
- -
- -
86.6%
Net Income, GAAP
- -
- -
-37.2%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-2.52
-4.18
-28.16
-16.24
-3.7
2025
-2.52
-0.61
-0.64
-0.44
-2.85
2026
-0.46
-0.48
-0.46
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Kalaris Therapeutics Inc. functions as a clinical-stage biopharmaceutical firm. The company is dedicated to advancing and commercializing innovative treatments for widespread retinal conditions. Its primary focus is on TH103, a distinguished anti-vascular endothelial growth factor (VEGF) investigational therapy. Engineered for enhanced VEGF inhibition and extended retention within the retina, TH103 acts as a fully humanized recombinant fusion protein, functioning as a decoy receptor. This therapy is currently being assessed in Phase 1 clinical trials for neovascular age-related macular degeneration (nAMD), with plans to expand its application to other neovascular and exudative retinal diseases, including diabetic macular edema (DME) and retinal vein occlusion (RVO). Kalaris recently completed a merger, securing substantial funding to support its ongoing clinical development efforts. The objective is to mitigate the limitations of existing therapies, aiming to lessen the treatment burden on patients.

Company News

  • Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update

  • Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Average Price Target of $18.75

  • Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

  • Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

  • Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% – Here’s What Happened

  • KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders

  • Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer

  • Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

  • Kalaris Appoints Laurie Keating to Board of Directors

  • Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

  • Kalaris to Present at Clinical Trials at the Summit 2026

  • Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

  • Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

  • Kalaris Therapeutics (NASDAQ:KLRS) Director Srinivas Akkaraju Buys 479,847 Shares of Stock

  • Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

  • Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

  • Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

  • Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

  • Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

  • Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates